ライフサイエンスコーパス: IL-5 receptor

1 al transducing receptor betac subunit of the IL-5 receptor.

2 nteraction with the alpha chain of the human IL-5 receptor.

3 ls and monocytes from patients expressed the IL-5 receptor.

4 s with the alpha subunit of the interleukin (IL) 5 receptor.

5 colony stimulating factor, and the IL-3 and IL-5 receptors.

6 We describe MVF assays for the IL-1 and IL-5 receptors.

7 Ras activation through the GM-CSF, IL-3, and IL-5 receptors.

8 onent of the GM-CSF, interleukin (IL)-3, and IL-5 receptors.

9 les in inflammation, the structural basis of IL-5 receptor activation remains unclear.

10 is regulated by the restricted expression of IL-5 receptor alpha (IL-5Ralpha), a subunit of high-affi

11 inistration of 3 doses of benralizumab (anti-IL-5 receptor alpha antibody [n = 5]) or placebo (n = 4)

12 oth monomers were shown to interact with the IL-5 receptor alpha chain with 1:1 stoichiometry and aff

13 al analysis revealed unexpected affinity for IL-5 receptor alpha chain with variants containing E110W

14 eosinophil-specific expression of the human IL-5 receptor alpha gene.

15 of biologics, such as benralizumab (an anti-IL-5 receptor alpha humanised monoclonal antibody), has

16 Treatment with antibodies targeting IL-5 or IL-5 receptor alpha reduces the frequency of asthma exac

17 Serum levels of IL-5 and IL-5 receptor alpha, but not IgE, were similarly increas

18 Benralizumab targets eosinophils by binding IL-5 receptor alpha, inducing apoptosis through antibody

19 The largely retained IL-5 receptor alpha-chain binding affinities versus rela

20 This mutein was found to retain substantial IL-5 receptor alpha-chain binding but with selectively s

21 This result confirms recent findings that IL-5 receptor alpha-chain recognition can be supported b

22 d benralizumab, a monoclonal antibody to the IL-5 receptor alpha-chain, are comparatively limited, es

23 x D region, which is predicted to engage the IL-5 receptor alpha-chain.

24 generated a 19-aa peptide that binds to the IL-5 receptor alpha/beta heterodimer complex with an aff

25 se findings highlight the cross-talk between IL-5 receptor and CD300f as a novel pathway regulating a

26 BM MCs expressed IL-5 receptor and other usual eosinophil cytokine/chemok

27 Resting B cells express few, if any, IL-5 receptors and do not respond to the lymphokine.

28 Thus, expression of IL-5 receptors and induction of Ig secretion requires co

29 sL(+) B cells expressed higher levels of the IL-5 receptor, and treating B cells with IL-5 and CD40L

30 sitization, leukotriene modifiers, anti-IL-5/IL-5 receptor, anti-IL-4 receptor, and anti-IgE) and inv

31 have shown that dynamin-2 interacts with the IL-5 receptor-associated tyrosine kinases, Lyn and JAK2,

32 p 2 region, which is predicted to engage the IL-5 receptor beta-chain.

33 the atopic sensitized tissues with either an IL-5 receptor blocking antibody (IL-5ra) or the human re

34 Furthermore, novel data demonstrate IL-5 receptor expression on neutrophils and monocytes in

35 ted monoclonal antibody directed against the IL-5 receptor, has powerful apoptotic effects on eosinop

36 ociate with beta common (betac) chain of the IL-5 receptor (IL-5betacR).

37 The IL-5 receptor (IL-5R) consists of an IL-5-specific alpha

38 logy is critically dependent on IL-5 and the IL-5 receptor (IL-5R), composed of a ligand binding alph

39 hils; in contrast, benralizumab binds to the IL-5 receptor (IL-5R), preventing IL-5 from binding and

40 kinase, is associated with the interleukin (IL)-5 receptor in eosinophils.

41 e a novel signaling pathway activated by the IL-5 receptor in eosinophils involving the CrkL adapter

42 zumab, and benralizumab, inhibit the IL-5 or IL-5 receptor pathway; dupilumab blocks IL-4 and IL-13 t

43 omers stimulated cell proliferation of human IL-5 receptor positive cells with a concentration depend

44 ortance of charge distribution in functional IL-5 receptor recruitment.

45 We tracked the oligomerization of IL-5 receptor subunits using fluorescence resonance ener

46 matopoietic functions through binding to the IL-5 receptor subunits, alpha and betac.

47 ces including interleukin (IL-)-3, IL-4, and IL-5 receptor subunits, the p65 component of nuclear fac

48 iEos had more IL-5 receptors than resident eosinophils (777.02 +/- 124

49 te the therapeutic benefit of inhibiting the IL-5 receptor using benralizumab to treat severe rhinosi

50 IL-5 receptor was also determined.

51 ding alpha-chain of the human interleukin 5 (IL-5) receptor was expressed in its soluble form, lackin

52 We found that HBEC expressed the IL-5 receptor, which triggered intracellular signaling a